1 Table of Contents 1 Table of Contents 4 1.1 List of Tables 5 1.2 List of Figures 7 2 Introduction 8 2.1 Male Health Report Coverage 8 2.2 Male Hypogonadism - Overview 8 2.3 Erectile Dysfunction - Overview 8 2.4 Benign Prostatic Hyperplasia - Overview 8 3 Therapeutics Development 9 3.1 Male Hypogonadism 9 3.2 Erectile Dysfunction 15 3.3 Benign Prostatic Hyperplasia 22 4 Therapeutics Assessment 29 4.1 Male Hypogonadism 29 4.2 Erectile Dysfunction 36 4.3 Benign Prostatic Hyperplasia 43 5 Companies Involved in Therapeutics Development 52 5.1 Male Hypogonadism 52 5.2 Erectile Dysfunction 58 5.3 Benign Prostatic Hyperplasia 71 6 Dormant Projects 84 6.1 Male Hypogonadism 84 6.2 Erectile Dysfunction 85 6.3 Benign Prostatic Hyperplasia 88 7 Discontinued Products 90 7.1 Male Hypogonadism 90 7.2 Erectile Dysfunction 90 7.3 Benign Prostatic Hyperplasia 91 8 Product Development Milestones 92 8.1 Male Hypogonadism 92 8.2 Erectile Dysfunction 103 8.3 Benign Prostatic Hyperplasia 111 9 Appendix 124 9.1 Methodology 124 9.2 Coverage 124 9.3 Secondary Research 124 9.4 Primary Research 124 9.5 Expert Panel Validation 124 9.6 Contact Us 125 9.7 Disclaimer 125

1.1 List of Tables Table 1: Number of Products under Development for Male Hypogonadism, H2 2017 9 Table 2: Number of Products under Development by Companies, H2 2017 11 Table 3: Number of Products under Development by Universities/Institutes, H2 2017 12 Table 4: Products under Development by Companies, H2 2017 13 Table 5: Products under Development by Universities/Institutes, H2 2017 14 Table 6: Number of Products under Development for Erectile Dysfunction, H2 2017 15 Table 7: Number of Products under Development by Companies, H2 2017 17 Table 8: Number of Products under Development by Universities/Institutes, H2 2017 18 Table 9: Products under Development by Companies, H2 2017 19 Table 10: Products under Development by Universities/Institutes, H2 2017 21 Table 11: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 22 Table 12: Number of Products under Development by Companies, H2 2017 24 Table 13: Number of Products under Development by Universities/Institutes, H2 2017 25 Table 14: Products under Development by Companies, H2 2017 26 Table 15: Products under Development by Universities/Institutes, H2 2017 28 Table 16: Number of Products by Stage and Target, H2 2017 30 Table 17: Number of Products by Stage and Mechanism of Action, H2 2017 32 Table 18: Number of Products by Stage and Route of Administration, H2 2017 34 Table 19: Number of Products by Stage and Molecule Type, H2 2017 36 Table 20: Number of Products by Stage and Target, H2 2017 37 Table 21: Number of Products by Stage and Mechanism of Action, H2 2017 39 Table 22: Number of Products by Stage and Route of Administration, H2 2017 41 Table 23: Number of Products by Stage and Molecule Type, H2 2017 43 Table 24: Number of Products by Stage and Target, H2 2017 45 Table 25: Number of Products by Stage and Mechanism of Action, H2 2017 47 Table 26: Number of Products by Stage and Route of Administration, H2 2017 49 Table 27: Number of Products by Stage and Molecule Type, H2 2017 51 Table 28: Male Hypogonadism - Pipeline by Antares Pharma Inc, H2 2017 52 Table 29: Male Hypogonadism - Pipeline by Clarus Therapeutics Inc, H2 2017 52 Table 30: Male Hypogonadism - Pipeline by EndoCeutics Inc, H2 2017 53 Table 31: Male Hypogonadism - Pipeline by Ferring International Center SA, H2 2017 53 Table 32: Male Hypogonadism - Pipeline by Lipocine Inc, H2 2017 54 Table 33: Male Hypogonadism - Pipeline by M et P Pharma AG, H2 2017 54 Table 34: Male Hypogonadism - Pipeline by Medlab Clinical Ltd, H2 2017 55 Table 35: Male Hypogonadism - Pipeline by Merck & Co Inc, H2 2017 55 Table 36: Male Hypogonadism - Pipeline by Mereo Biopharma Group Plc, H2 2017 56 Table 37: Male Hypogonadism - Pipeline by Repros Therapeutics Inc, H2 2017 56 Table 38: Male Hypogonadism - Pipeline by TesoRx Pharma LLC, H2 2017 57 Table 39: Male Hypogonadism - Pipeline by The Female Health Company, H2 2017 58 Table 40: Male Hypogonadism - Pipeline by Viramal Ltd, H2 2017 58 Table 41: Erectile Dysfunction - Pipeline by Apricus Biosciences Inc, H2 2017 58 Table 42: Erectile Dysfunction - Pipeline by Astellas Pharma Inc, H2 2017 59 Table 43: Erectile Dysfunction - Pipeline by Biolab Farmaceutica Ltda, H2 2017 59 Table 44: Erectile Dysfunction - Pipeline by Biopharm GmbH, H2 2017 60 Table 45: Erectile Dysfunction - Pipeline by Can-Fite BioPharma Ltd, H2 2017 60 Table 46: Erectile Dysfunction - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2017 61 Table 47: Erectile Dysfunction - Pipeline by Futura Medical Plc, H2 2017 61 Table 48: Erectile Dysfunction - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 62 Table 49: Erectile Dysfunction - Pipeline by Humanetics Corp, H2 2017 62 Table 50: Erectile Dysfunction - Pipeline by IntelGenx Corp, H2 2017 63 Table 51: Erectile Dysfunction - Pipeline by Ion Channel Innovations LLC, H2 2017 63 Table 52: Erectile Dysfunction - Pipeline by iX Biopharma Ltd, H2 2017 64 Table 53: Erectile Dysfunction - Pipeline by Mezzion Pharma Co Ltd, H2 2017 64 Table 54: Erectile Dysfunction - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 65 Table 55: Erectile Dysfunction - Pipeline by Monosol Rx LLC, H2 2017 65 Table 56: Erectile Dysfunction - Pipeline by N4 Pharma Plc, H2 2017 66 Table 57: Erectile Dysfunction - Pipeline by NAL Pharmaceuticals Ltd, H2 2017 66 Table 58: Erectile Dysfunction - Pipeline by Nanoform Cardiovascular Therapeutics Ltd, H2 2017 67 Table 59: Erectile Dysfunction - Pipeline by Palatin Technologies Inc, H2 2017 67 Table 60: Erectile Dysfunction - Pipeline by Pharmicell Co Ltd, H2 2017 68 Table 61: Erectile Dysfunction - Pipeline by SK Chemicals Co Ltd, H2 2017 68 Table 62: Erectile Dysfunction - Pipeline by Suda Ltd, H2 2017 69 Table 63: Erectile Dysfunction - Pipeline by XuanZhu Pharma Co Ltd, H2 2017 69 Table 64: Erectile Dysfunction - Pipeline by Yangtze River Pharmaceutical Group, H2 2017 70 Table 65: Erectile Dysfunction - Pipeline by Yungjin Pharm Co Ltd, H2 2017 70 Table 66: Benign Prostatic Hyperplasia - Pipeline by Addex Therapeutics Ltd, H2 2017 71 Table 67: Benign Prostatic Hyperplasia - Pipeline by AndroScience Corp, H2 2017 71 Table 68: Benign Prostatic Hyperplasia - Pipeline by Aphios Corp, H2 2017 72 Table 69: Benign Prostatic Hyperplasia - Pipeline by BCWorld Pharm Co Ltd, H2 2017 72 Table 70: Benign Prostatic Hyperplasia - Pipeline by Biolab Farmaceutica Ltda, H2 2017 73 Table 71: Benign Prostatic Hyperplasia - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017 73 Table 72: Benign Prostatic Hyperplasia - Pipeline by Curadis GmbH, H2 2017 74 Table 73: Benign Prostatic Hyperplasia - Pipeline by Dongkook Pharmaceutical Co Ltd, H2 2017 74 Table 74: Benign Prostatic Hyperplasia - Pipeline by GL Pharm Tech Corp, H2 2017 75 Table 75: Benign Prostatic Hyperplasia - Pipeline by Health Ever Bio-Tech Co Ltd, H2 2017 75 Table 76: Benign Prostatic Hyperplasia - Pipeline by Jeil Pharmaceutical Co Ltd, H2 2017 76 Table 77: Benign Prostatic Hyperplasia - Pipeline by MEI Pharma Inc, H2 2017 76 Table 78: Benign Prostatic Hyperplasia - Pipeline by Meiji Seika Pharma Co Ltd, H2 2017 77 Table 79: Benign Prostatic Hyperplasia - Pipeline by Mezzion Pharma Co Ltd, H2 2017 77 Table 80: Benign Prostatic Hyperplasia - Pipeline by Nymox Pharmaceutical Corp, H2 2017 78 Table 81: Benign Prostatic Hyperplasia - Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 78 Table 82: Benign Prostatic Hyperplasia - Pipeline by OPKO Health Inc, H2 2017 79 Table 83: Benign Prostatic Hyperplasia - Pipeline by SK Chemicals Co Ltd, H2 2017 79 Table 84: Benign Prostatic Hyperplasia - Pipeline by Sophiris Bio Inc, H2 2017 80 Table 85: Benign Prostatic Hyperplasia - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 80 Table 86: Benign Prostatic Hyperplasia - Pipeline by The Female Health Company, H2 2017 81 Table 87: Benign Prostatic Hyperplasia - Pipeline by XuanZhu Pharma Co Ltd, H2 2017 81 Table 88: Benign Prostatic Hyperplasia - Pipeline by Yungjin Pharm Co Ltd, H2 2017 82 Table 89: Benign Prostatic Hyperplasia - Pipeline by Yuyu Pharma Inc, H2 2017 83 Table 90: Male Hypogonadism - Dormant Projects, H2 2017 84 Table 91: Erectile Dysfunction - Dormant Projects, H2 2017 85 Table 92: Benign Prostatic Hyperplasia - Dormant Projects, H2 2017 88 Table 93: Male Hypogonadism - Discontinued Products, H2 2017 90 Table 94: Erectile Dysfunction - Discontinued Products, H2 2017 90 Table 95: Benign Prostatic Hyperplasia - Discontinued Products, H2 2017 91 1.2 List of Figures Figure 1: Number of Products under Development for Male Hypogonadism, H2 2017 9 Figure 2: Number of Products under Development by Companies, H2 2017 10 Figure 3: Number of Products under Development for Erectile Dysfunction, H2 2017 15 Figure 4: Number of Products under Development by Companies, H2 2017 16 Figure 5: Number of Products under Development by Universities/Institutes, H2 2017 18 Figure 6: Number of Products under Development for Benign Prostatic Hyperplasia, H2 2017 22 Figure 7: Number of Products under Development by Companies, H2 2017 23 Figure 8: Number of Products under Development by Universities/Institutes, H2 2017 25 Figure 9: Number of Products by Targets, H2 2017 29 Figure 10: Number of Products by Stage and Targets, H2 2017 29 Figure 11: Number of Products by Mechanism of Actions, H2 2017 31 Figure 12: Number of Products by Stage and Mechanism of Actions, H2 2017 31 Figure 13: Number of Products by Routes of Administration, H2 2017 33 Figure 14: Number of Products by Stage and Routes of Administration, H2 2017 33 Figure 15: Number of Products by Molecule Types, H2 2017 35 Figure 16: Number of Products by Stage and Molecule Types, H2 2017 35 Figure 17: Number of Products by Top 10 Targets, H2 2017 36 Figure 18: Number of Products by Stage and Top 10 Targets, H2 2017 37 Figure 19: Number of Products by Top 10 Mechanism of Actions, H2 2017 38 Figure 20: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 38 Figure 21: Number of Products by Routes of Administration, H2 2017 40 Figure 22: Number of Products by Stage and Routes of Administration, H2 2017 40 Figure 23: Number of Products by Molecule Types, H2 2017 42 Figure 24: Number of Products by Stage and Molecule Types, H2 2017 42 Figure 25: Number of Products by Top 10 Targets, H2 2017 43 Figure 26: Number of Products by Stage and Top 10 Targets, H2 2017 44 Figure 27: Number of Products by Top 10 Mechanism of Actions, H2 2017 46 Figure 28: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 46 Figure 29: Number of Products by Routes of Administration, H2 2017 48 Figure 30: Number of Products by Stage and Routes of Administration, H2 2017 48 Figure 31: Number of Products by Molecule Types, H2 2017 50 Figure 32: Number of Products by Stage and Molecule Types, H2 2017 50